Skip to main content
. 2016 Mar 29;13:22. doi: 10.1186/s12977-016-0255-z

Fig. 4.

Fig. 4

CCR5 agonist MIP-1β enhances R3A-5/6AA pathogenesis to promote bystander CD4 T cell depletion PBMCs were infected with R3A-5/6AA virus and treated with recombinant MIP-1 β (200 ng/mL) at 3 h post infection. At 6 days post infection, viabilities of p24(−) and p24(+) CD4 T cell were measured as described in Fig. 1c. a Representative FACS plots and b graphical summary are presented. c %CD4 T cells survival at 6 days post infection was measured by gating on live CD8(−) CD3(+) cells. *p < 0.05